We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Blood Test Predicts Organ Transplant Rejection in Six Hours

By LabMedica International staff writers
Posted on 13 Oct 2022
Print article
Image: The PlexAPR blood test rapidly measures rejection risk of transplanted abdominal organs (Photo courtesy of Pexels)
Image: The PlexAPR blood test rapidly measures rejection risk of transplanted abdominal organs (Photo courtesy of Pexels)

Patients receiving solid organ transplants can face rejection due to recipient T-cells which injure the transplanted organ directly, or anti-donor antibodies, which are produced by B-cells of the recipient. Rejection is diagnosed with biopsies which are performed when dysfunction of the transplanted organ is suspected from clinical symptoms and blood tests. However, biopsies are invasive, take time to arrange and do not clearly distinguish between some types of viral infection which may co-exist with rejection. Rapid non-invasive surveillance of organ health can improve survival and quality of life after transplantation. Now, a six-hour blood test to predict organ transplant rejection will allow clinicians to react sooner and improve management of transplanted organs experiencing organ dysfunction, while confirmatory biopsies are being arranged.

Plexision (Pittsburgh, PA, USA) has completed development of PlexAPR - a six-hour blood test to predict organ transplant rejection. When combined with other clinical and laboratory information, rapid rejection-risk assessment can allow caregivers to intervene early, while arranging confirmatory biopsies, or during lifelong surveillance of organ health. PlexAPR is based on the presentation of donor antigen by circulating antigen presenting cells, such as B-cells. The test readout is a personalized index, only applicable to the patient being tested. Patient samples will be tested at the company’s CLIA- and CAP-accredited reference laboratory.

“Transplant rejection can happen at any time after transplantation and requires lifelong management of anti-rejection medications. Same-day delivery of test results is a valuable addition to personalized rejection-risk assessment and improving outcomes,” said Rajeev Sindhi, CEO of Plexision.

Related Links:
Plexision

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.